• Logo
  • SBMUJournals

Evaluation of Thimerosal on the Potency and Stability of Inactivated Animal Rabies Vaccine

Farzaneh Ahmadnejad, Nargess Miandehi, Alireza Gholami, Mohammad Chehrazi, Saeed Jodairi Eslami, Ali Moradi-Joshaghan, Zohreh Parhizkar, Bahram Roshanaei
0

Views

PDF

Abstract

Thimerosal is used as a preservative in Rabies vaccine. This study aimed at comparing potency and stability of inactivated animal rabies vaccine with and without thimerosal. Therefore, two groups of rabies vaccine were produced. The results indicated that thimerosal has no deleterious effect on the vaccine; furthermore, its elimination did not influence the potency and stability of the vaccine.

 

 

 

 

 

 


Keywords

Thimerosal, Potency, Rabies vaccine

References

Meslin F-X, Kaplan MM, Koprowski H. Laboratory techniques in rabies. 4th ed ed. Geneva: World Health Organization; 1996.

Food and Drug Administration (FDA). Thimerosal and Vaccines [(Accessed 2017 Sep 10)]. Available from: https://www.fda.gov/biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm096228.htm

Geier DA, Jordan SK, Geier MR. The relative toxicity of compounds used as preservatives in vaccines and biologics. Medical science monitor : international medical journal of experimental and clinical research. 2010 May;16(5):SR21-7. PubMed PMID: 20424565.

Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environmental health perspectives. 2005;113(8):1015-21.

Products CfPM. European medicines agency. CPMP/BwP/2517/00: Points to consider on the reduction, elimination or substitution of thiomersal in vaccines. 2001.

Olczak M, Duszczyk M, Mierzejewski P, Majewska MD. Neonatal administration of a vaccine preservative, thimerosal, produces lasting impairment of nociception and apparent activation of opioid system in rats. Brain research. 2009 Dec 8;1301:143-51. PubMed PMID: 19747466.

Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006 Jul;118(1):e139-50. PubMed PMID: 16818529.

Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. The New England journal of medicine. 2007 Sep 27;357(13):1281-92. PubMed PMID: 17898097.

Baskin DS, Ngo H, Didenko VV. Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts. Toxicological sciences : an official journal of the Society of Toxicology. 2003 Aug;74(2):361-8. PubMed PMID: 12773768. Pubmed Central PMCID: 1892749.

Dórea JG. Integrating experimental (in vitro and in vivo) neurotoxicity studies of low-dose thimerosal relevant to vaccines. Neurochemical research. 2011;36(6):927-38.

Olczak M, Duszczyk M, Mierzejewski P, Wierzba-Bobrowicz T, Majewska MD. Lasting neuropathological changes in rat brain after intermittent neonatal administration of thimerosal. Folia neuropathologica. 2010;48(4):258-69. PubMed PMID: 21225508.

Kravchenko AT, Dzagurov SG, Chervonskaia GP. [Evaluation of the toxic action of prophylactic and therapeutic preparations on cell cultures. III. The detection of toxic properties in medical biological preparations by the degree of cell damage in the L132 continuous cell line]. Zhurnal mikrobiologii, epidemiologii, i immunobiologii. 1983 Mar(3):87-92. PubMed PMID: 6845931. Otsenka toksicheskogo deistviia profilakticheskikh i lechebnykh preparatov na kul'turakh kletok. Soobshchenie III. Vyiavlenie toksicheskikh svoistv v meditsinskikh biologicheskikh preparatakh po stepeni povrezhrdeniia kletk v perebvivaemoi linii L132.

Ni J, Bi S, Xu W, Zhang C, Lu Y, Zhai L, et al. Improved immune response to an attenuated pseudorabies virus vaccine by ginseng stem-leaf saponins (GSLS) in combination with thimerosal (TS). Antiviral research. 2016 Aug;132:92-8. PubMed PMID: 27241688.

Jamieson W, Powell H. Merthiolate as a preservative for biological products. American journal of epidemiology. 1931;14(1):218-24.

Blair A, Clark B, Clarke AJ, Wood P. Tissue concentrations of mercury after chronic dosing of squirrel monkeys with thiomersal. Toxicology. 1975;3(2):171-6. PubMed PMID: 804725.

Geier DA, Sykes LK, Geier MR. A review of Thimerosal (Merthiolate) and its ethylmercury breakdown product: specific historical considerations regarding safety and effectiveness. Journal of toxicology and environmental health Part B, Critical reviews. 2007 Dec;10(8):575-96. PubMed PMID: 18049924.

Van Damme P, von Sonnenburg F, Hatz C, Hoet B, Lefevre I, Leyssen M. Long‐term immunogenicity of preservative‐free hepatitis B vaccine formulations in adults. Journal of medical virology. 2009;81(10):1710-5.

Sawyer LA, McInnis J, Patel A, Horne AD, Albrecht P. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine. 1994 Jul;12(9):851-6. PubMed PMID: 7526574.

Gama Ker H, Dian de Oliveira Aguiar-Soares R, Mendes Roatt B, das Dores Moreira N, Coura-Vital W, Martins Carneiro C, et al. Effect of the preservative and temperature conditions on the stability of Leishmania infantum promastigotes antigens applied in a flow cytometry diagnostic method for canine visceral leishmaniasis. Diagnostic microbiology and infectious disease. 2013 Aug;76(4):470-6. PubMed PMID: 23726649.




DOI: https://doi.org/10.22037/aab.v10i3.26363

Refbacks

  • There are currently no refbacks.